Download Image
    
Share
  
Post
Silymarin for COVID-19
1 study with 50 patients
Hospital Icon Control
Hospital Icon Silymarin Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Silymarin studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -20% Hospitalization 8% RCTs -20% Late -20% Favorssilymarin Favorscontrol
Sep 16
2024
 Emam et al., AMB Express, doi:10.1186/s13568-024-01739-8 Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors
In vitro study showing that curcumin, quercetin, gallic acid, and silymarin inhibit SARS-CoV-2 spike protein binding to the ACE2 receptor. Authors developed a novel immunofluorescent assay to screen potential inhibitors of the spike-ACE2 ..
Jul 20
2022
 Aryan et al., Phytotherapy Research, doi:10.1002/ptr.7537 Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial
20% higher need for oxygen therapy (p=0.78) and 8% shorter hospitalization (p=0.5). RCT 50 hospitalized COVID-19 patients showing no significant difference in symptom resolution time or hospitalization duration with nano-silymarin treatment.